Inclusion Criteria:

- Subjects must have measurable disease OR must be evaluable for disease progression

- Age >/= 18 years.

- Postmenopausal women

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

- Histologically or cytologically confirmed ER and/or PgR positive carcinoma of the
breast with unresectable, locally advanced and/or metastatic disease

- Subjects must have received prior hormonal therapy for the treatment of breast cancer
(anastrozole, letrozole, or tamoxifen)

- Adequate hematologic, hepatic, and renal function

Exclusion Criteria:

- Prior use of exemestane or pazopanib

- Premenopausal women

- Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is
progressing in severity.

- Prior therapy with a VEGF inhibitor.

- Use of an investigational agent, including an investigational anti-cancer agent,
within 28 days or 5 half-lives, whichever is longer, prior to the first dose of
investigational product.

- Evidence of recurrence or active disease from prior malignancy.

- Clinically significant gastrointestinal abnormalities that may increase the risk for
GI bleeding or affect the absorption of the investigational product(s).

- Presence of uncontrolled infection.

- History of any major cardiovascular conditions within the past 6 months:

- Poorly controlled hypertension

- History of cerebrovascular accident, pulmonary embolism or untreated deep venous
thrombosis (DVT) within the past 6 months.

- Prior major surgery or trauma within 28 days prior to first dose of investigational
product and/or presence of any non-healing wound, fracture, or ulcer

- Evidence of active bleeding or bleeding tendency.